Lamictal Articles
More Japanese drug OKs: GSK’s Rotarix and Lamictal; Takeda’s Liovel and new use for Eisai/Abbott’s Humira
4 July 2011
GlaxoSmithKline gets US FDA warning on aseptic meningitis risk with seizure drug Lamictal; favored investment by UBS analyst
16 August 2010
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
US FDA clears new uses for two GlaxoSmithKline drugs; Tykerb and Lamictal; GSK set to announce 3,000 job cuts
1 February 2010
GlaxoSmithKline beats forecasts with 3rd quarter2009 profits leaping 34%, despite generic competition
28 October 2009
Anti-epileptics to get suicide warnings in USA
22 December 2008
Stock Commentary - New York week to Sept 1, 2008
8 September 2008
Teva debuts first generic Lamictal
28 July 2008
GSK sees 2008 EPS fall; posts 2007 results
18 February 2008
Patent expiry for 2008 provides generic opportunity
14 January 2008
GSK's Lamictal XR cut partial seizures 46%
14 May 2007
GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure
30 April 2007
GSK's full-year 2006 turnover up 7%
12 February 2007
GSK's Lamictal linked to babies' cleft palates
9 October 2006
Torrent opens Australian unit with six new NDAs
18 September 2006
Strong data for GSK's Lamictal in new indication
7 August 2006
Consilient moves into UK and Dutch generics market
22 August 2005
GSK EPS rises 10% on 6% sales growth
8 August 2005
Teva's 2nd-qtr lifted by non-US business
8 August 2005
GlaxoSmithKline sees 10% EPS rise on 6% sales growth
1 August 2005
UK NICE OKs Novartis' Gleevec as first-line GIST management, also views epilepsy care
8 November 2004
Studies reveal risk of birth defects from AEDs
13 September 2004
UK NICE guidance on insomnia drugs
10 May 2004
GSK's 1st-qtr profit continues decline
10 May 2004
UK NICE backs newer antiepileptics
29 March 2004
GSK's Lamictal gets expanded indication
26 January 2004
GSK gains FDA OK for new Lamictal use
7 July 2003
Update: GSK 2002 results boosted by 13% growth in US sales
17 February 2003
GlaxoSmithKline 2002 results boosted by 13% growth in US sales
17 February 2003
Stock Commentary - Week to January 27 - Europe
3 February 2003
GSK's Lamictal cleared for wider pediatric use
27 January 2003
GSK plans six product filings in 2002
18 February 2002
GlaxoSmithKline censured for abuse of market dominance in Greece
22 October 2001
Euro epilepsy drug sales "to grow 17.2%/year"
19 February 2001
GW's Lamictal shows benefits over older drug
12 October 2000
Parkinson's market "may double by 2008"
22 February 2000
UCB Pharma's levetiracetam, Phase III data show efficacy in epilepsy
14 September 1999
Duramed's Cenestin available in USA
22 July 1999
G-W's Ziagen approved in USA
21 December 1998
Advances In CNS Therapeutics Reviewed By Lehman Analysts
30 November 1998
Lamictal Approval For Lennox-Gastaut
1 September 1998
UK Pharma Leaders Outline Strategy
22 June 1998
GW's Lamictal In Bipolar Disorder
18 June 1998
Clinical Trial News In Brief
28 May 1998
Epilepsy Market Sees Strong Growth
29 July 1997
EUROPEAN AND LONDON STOCK COMMENT
10 April 1997
Glaxo Wellcome Issues Lamictal Warning
9 April 1997
Glaxo Wellcome 1996 Product Performance
17 March 1997
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
Zantac Sales Slide 4% At Glaxo Wellcome
11 March 1996
Losec "Will Be The World's Top-Selling Drug In 2000"
26 February 1996
Higher-Priced Drugs Set To Expand Epilepsy Market
12 February 1996
Prix Galien For Roche And Glaxo Wellcome
29 January 1996
US Drug Lag Does Not Exist, Claims FDA Study
15 January 1996
Glaxo Wellcome Unveils Revamped Pipeline
20 November 1995
Prospects For Glutamate Antagonists In Stroke
18 September 1995
Focus On NPS Pharma: Calcium Specialist
29 May 1995
Lamictal News
27 February 1995
Robb Claims Wellcome Is Undervalued By Glaxo
20 February 1995
European Stock Comment
13 February 1995
Lamictal Launched As Monotherapy In UK
13 February 1995
Do Wellcome Results Justify Higher Bid
6 February 1995
Glaxo, Wellcome Product Lines Are Complementary
6 February 1995
FDA C'tee Gives Thumbs Down For OTC Zovirax
23 January 1995
Fast FDA Approvals Of User-Fee NMEs In 1994
16 January 1995
FDA Approves BW's Lamictal
9 January 1995
Burroughs Wellcome Outlook Reviewed
19 December 1994
FDA Sends Warning Letter To BW
19 December 1994
Monotherapy Filing For Lamotrigine In UK
26 September 1994
LAMICTAL "APPROVABLE"
8 August 1994
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
